<DOC>
	<DOCNO>NCT00534222</DOCNO>
	<brief_summary>With observational study want examine intensity agitation , intensity psychotic symptom presence sleep disorder predict success treatment atypical antipsychotic 12 week treatment patient psychotic and/or manic episode . In study examine percentage patient 2-point improvement CGI-scale . Of group , responder , retrospective profile responder analyse ( key-factors confounders ) . PLEASE NOTE : Seroquel SR Seroquel XR refer formulation . The SR designation change XR consultation FDA .</brief_summary>
	<brief_title>Unraveling Relation Patient 's Profile Therapeutical Effects Atypicals , Including Quetiapine Effect</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Patients manic episode patient diagnose schizophrenia ( psychotic episode ) Patients start treatment atypical antipsychotic : quetiapine , olanzapine risperidone Patients prepared consent make cod data available AstraZeneca Patients CGI â‰¥ 4 Patients serious underlying disease ( include renal hepatic insufficiency , cancer , cardiovascular disease suchlike ) . Contraindications quetiapine , olanzapine risperidone accord SmPC product Patients unable give inform consent accord attend physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Patients manic episode</keyword>
	<keyword>Patients diagnose w/schizophrenia , start treatment atypical antipsychotic &amp; least scored moderately ill CGI baseline</keyword>
</DOC>